Enhanced bone regeneration via multimodal actions of synthetic peptide SVVYGLR on osteoprogenitors and osteoclasts

Biomaterials

Volumn 30, Issue 27, 2009, Pages 4676-4686

  Egusa, Hiroshi ^a   Kaneda, Yoshitoshi ^a   Akashi, Yoshihiro ^a   Hamada, Yoshinosuke ^b   Matsumoto, Takuya ^a   Saeki, Makio ^a   Thakor, Devang K ^c   Tabata, Yasuhiko ^c   Matsuura, Nariaki ^b   Yatani, Hirofumi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Bone regeneration; Mesenchymal stem cells; Osteoclasts; Peptide; SVVYGLR

Indexed keywords

BINDING SEQUENCE; BIOACTIVE PEPTIDES; BONE DEFECT; BONE FORMATION; BONE MARROW-DERIVED MESENCHYMAL STEM CELLS; BONE REGENERATION; BONE TISSUE REGENERATION; COLLAGEN SPONGE; GRAFTED COLLAGEN; HUMAN MESENCHYMAL CELLS; IN-CELL; INTEGRIN; MESENCHYMAL STEM CELLS; MULTI-MODAL; MULTINUCLEATED CELLS; NFAT ACTIVITY; OSTEOCLASTOGENESIS; OSTEOCLASTS; OSTEOGENIC CELLS; OSTEOPONTIN; OSTEOPROGENITOR CELLS; OSTEOPROGENITORS; PEPTIDE GROUPS; POTENTIAL APPLICATIONS; RGD SEQUENCES; SVVYGLR; SYNTHETIC PEPTIDE;

BONE; CELL CULTURE; CELL MEMBRANES; COLLAGEN; GRAFTING (CHEMICAL); RAT CONTROL;

AMINES;

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; COLLAGEN SPONGE; MESSENGER RNA; SERYLVALYLVALYLTYROSYLGLYCYLLEUCYLARGININE; SYNTHETIC PEPTIDE; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE REGENERATION; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKULL DEFECT; THERAPY EFFECT;

ADULT; AMINO ACID SEQUENCE; ANIMALS; BONE REGENERATION; CALCIFICATION, PHYSIOLOGIC; CELL ADHESION; CELL LINE; CELL PROLIFERATION; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MESENCHYMAL STEM CELLS; MICE; MOLECULAR SEQUENCE DATA; OSTEOCLASTS; OSTEOGENESIS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; SKULL; STEM CELLS;

MURINAE; RATTUS;

EID: 67651174290     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.05.032     Document Type: Article

References (41)

1. Allori A.C., Sailon A.M., and Warren S.M. Biological basis of bone formation, remodeling, and repair-part I: biochemical signaling molecules. Tissue Eng Part B Rev 14 (2008) 259-273
2. Reichert J.C., Saifzadeh S., Wullschleger M.E., Epari D.R., Schutz M.A., Duda G.N., et al. The challenge of establishing preclinical models for segmental bone defect research. Biomaterials 30 (2009) 2149-2163
3. Wikesjo U.M., Polimeni G., and Qahash M. Tissue engineering with recombinant human bone morphogenetic protein-2 for alveolar augmentation and oral implant osseointegration: experimental observations and clinical perspectives. Clin Implant Dent Relat Res 7 (2005) 112-119
4. Smith D.M., Cooper G.M., Mooney M.P., Marra K.G., and Losee J.E. Bone morphogenetic protein 2 therapy for craniofacial surgery. J Craniofac Surg 19 (2008) 1244-1259
5. Kodama N., Nagata M., Tabata Y., Ozeki M., Ninomiya T., and Takagi R. A local bone anabolic effect of rhFGF2-impregnated gelatin hydrogel by promoting cell proliferation and coordinating osteoblastic differentiation. Bone (2008)
6. Kantlehner M., Schaffner P., Finsinger D., Meyer J., Jonczyk A., Diefenbach B., et al. Surface coating with cyclic RGD peptides stimulates osteoblast adhesion and proliferation as well as bone formation. Chembiochem 1 (2000) 107-114
7. Itoh D., Yoneda S., Kuroda S., Kondo H., Umezawa A., Ohya K., et al. Enhancement of osteogenesis on hydroxyapatite surface coated with synthetic peptide (EEEEEEEPRGDT) in vitro. J Biomed Mater Res 62 (2002) 292-298
8. Reyes C.D., Petrie T.A., Burns K.L., Schwartz Z., and Garcia A.J. Biomolecular surface coating to enhance orthopaedic tissue healing and integration. Biomaterials 28 (2007) 3228-3235
9. Yokosaki Y., Matsuura N., Sasaki T., Murakami I., Schneider H., Higashiyama S., et al. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 274 (1999) 36328-36334
10. Barry S.T., Ludbrook S.B., Murrison E., and Horgan C.M. Analysis of the alpha4beta1 integrin-osteopontin interaction. Exp Cell Res 258 (2000) 342-351
11. Green P.M., Ludbrook S.B., Miller D.D., Horgan C.M., and Barry S.T. Structural elements of the osteopontin SVVYGLR motif important for the interaction with alpha(4) integrins. FEBS Lett 503 (2001) 75-79
12. Hamada Y., Nokihara K., Okazaki M., Fujitani W., Matsumoto T., Matsuo M., et al. Angiogenic activity of osteopontin-derived peptide SVVYGLR. Biochem Biophys Res Commun 310 (2003) 153-157
13. Hamada Y., Yuki K., Okazaki M., Fujitani W., Matsumoto T., Hashida M.K., et al. Osteopontin-derived peptide SVVYGLR induces angiogenesis in vivo. Dent Mater J 23 (2004) 650-655
14. Hamada Y., Egusa H., Kaneda Y., Hirata I., Kawaguchi N., Hirao T., et al. Synthetic osteopontin-derived peptide SVVYGLR can induce neovascularization in artificial bone marrow scaffold biomaterials. Dent Mater J 26 (2007) 487-492
15. Kanczler J.M., and Oreffo R.O. Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cell Mater 15 (2008) 100-114
16. Sodek J., Ganss B., and McKee M.D. Osteopontin. Crit Rev Oral Biol Med 11 (2000) 279-303
17. Gravallese E.M. Osteopontin: a bridge between bone and the immune system. J Clin Invest 112 (2003) 147-149
18. Lai C.F., Seshadri V., Huang K., Shao J.S., Cai J., Vattikuti R., et al. An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res 98 (2006) 1479-1489
19. Yamamoto N., Sakai F., Kon S., Morimoto J., Kimura C., Yamazaki H., et al. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest 112 (2003) 181-188
20. Yamamoto N., Nakashima T., Torikai M., Naruse T., Morimoto J., Kon S., et al. Successful treatment of collagen-induced arthritis in non-human primates by chimeric anti-osteopontin antibody. Int Immunopharmacol 7 (2007) 1460-1470
21. Tsutsumi S., Shimazu A., Miyazaki K., Pan H., Koike C., Yoshida E., et al. Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. Biochem Biophys Res Commun 288 (2001) 413-419
22. Nikawa H., Egusa H., Makihira S., Okamoto T., Kurihara H., Shiba H., et al. An in vitro evaluation of the adhesion of Candida species to oral and lung tissue cells. Mycoses 49 (2006) 14-17
23. Itoh K., Udagawa N., Kobayashi K., Suda K., Li X., Takami M., et al. Lipopolysaccharide promotes the survival of osteoclasts via Toll-like receptor 4, but cytokine production of osteoclasts in response to lipopolysaccharide is different from that of macrophages. J Immunol 170 (2003) 3688-3695
24. Kikkawa H., Kaihou M., Horaguchi N., Uchida T., Imafuku H., Takiguchi A., et al. Role of integrin alpha(v)beta3 in the early phase of liver metastasis: PET and IVM analyses. Clin Exp Metastasis 19 (2002) 717-725
25. Egusa H., Iida K., Kobayashi M., Lin T.Y., Zhu M., Zuk P.A., et al. Downregulation of extracellular matrix-related gene clusters during osteogenic differentiation of human bone marrow- and adipose tissue-derived stromal cells. Tissue Eng 13 (2007) 2589-2600
26. Egusa H., Schweizer F.E., Wang C.C., Matsuka Y., and Nishimura I. Neuronal differentiation of bone marrow-derived stromal stem cells involves suppression of discordant phenotypes through gene silencing. J Biol Chem 280 (2005) 23691-23697
27. Lee F.Y., Kim D.W., Karmin J.A., Hong D., Chang S.S., Fujisawa M., et al. mu-Calpain regulates receptor activator of NF-kappaB ligand (RANKL)-supported osteoclastogenesis via NF-kappaB activation in RAW 264.7 cells. J Biol Chem 280 (2005) 29929-29936
28. Monchaux E., and Vermette P. Bioactive microarrays immobilized on low-fouling surfaces to study specific endothelial cell adhesion. Biomacromolecules 8 (2007) 3668-3673
29. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69 (1992) 11-25
30. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 110 (2002) 673-687
31. Shattil S.J. Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Thromb Haemost 74 (1995) 149-155
32. Moiseeva E.P. Adhesion receptors of vascular smooth muscle cells and their functions. Cardiovasc Res 52 (2001) 372-386
33. Cheng S.L., Lai C.F., Blystone S.D., and Avioli L.V. Bone mineralization and osteoblast differentiation are negatively modulated by integrin alpha(v)beta3. J Bone Miner Res 16 (2001) 277-288
34. Liu S., Thomas S.M., Woodside D.G., Rose D.M., Kiosses W.B., Pfaff M., et al. Binding of paxillin to alpha4 integrins modifies integrin-dependent biological responses. Nature 402 (1999) 676-681
35. Young B.A., Taooka Y., Liu S., Askins K.J., Yokosaki Y., Thomas S.M., et al. The cytoplasmic domain of the integrin alpha9 subunit requires the adaptor protein paxillin to inhibit cell spreading but promotes cell migration in a paxillin-independent manner. Mol Biol Cell 12 (2001) 3214-3225
36. Takayanagi H. The role of NFAT in osteoclast formation. Ann N Y Acad Sci 1116 (2007) 227-237
37. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7 (2007) 292-304
38. Rao H., Lu G., Kajiya H., Garcia-Palacios V., Kurihara N., Anderson J., et al. Alpha9beta1: a novel osteoclast integrin that regulates osteoclast formation and function. J Bone Miner Res 21 (2006) 1657-1665
39. Choi S.J., Han J.H., and Roodman G.D. ADAM8: a novel osteoclast stimulating factor. J Bone Miner Res 16 (2001) 814-822
40. Rauch F. Bone growth in length and width: the Yin and Yang of bone stability. J Musculoskelet Neuronal Interact 5 (2005) 194-201
41. Kojima T., Amizuka N., Suzuki A., de Freitas P.H., Yoshizawa M., Kudo A., et al. Histological examination of bone regeneration achieved by combining grafting with hydroxyapatite and thermoplastic bioresorbable plates. J Bone Miner Metab 25 (2007) 361-373